Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinsuke Iida

Showing results (201-210 of 290) with videos related to

Pageof 29
Sort By:
Scientific Reports|May 11, 2019
Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma CellsHiroyuki Yamazaki, Kotaro Shirakawa, Tadahiko Matsumoto, et al.
Cancer Science|July 24, 2019
Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 studyShinsuke Iida, Takashi Watanabe, Morio Matsumoto, et al.
International Journal of Hematology|April 15, 2021
Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patientsMorio Matsumoto, Kenshi Suzuki, Junya Kuroda, et al.
International Journal of Hematology|September 6, 2015
Overexpression of salivary-type amylase reduces the sensitivity to bortezomib in multiple myeloma cellsShohei Mizuno, Ichiro Hanamura, Akinobu Ota, et al.
Cancer Science|October 29, 2017
Clinical significance of tryptophan catabolism in Hodgkin lymphomaAyako Masaki, Takashi Ishida, Yasuhiro Maeda, et al.
International Journal of Hematology|December 31, 2015
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myelomaHaruhito Totani, Masaki Ri, Chie Kato, et al.
Oncotarget|March 9, 2018
Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunitsTakashi Yoshida, Masaki Ri, Takashi Kanamori, et al.
British Journal of Haematology|August 18, 2021
Clinical significance of TP53 mutations in adult T-cell leukemia/lymphomaYuma Sakamoto, Takashi Ishida, Ayako Masaki, et al.
Haematologica|August 5, 2018
Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphomaShiori Kinoshita, Takashi Ishida, Asahi Ito, et al.
Cancer Science|September 6, 2008
Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myelomaHiroki Yano, Satoshi Kayukawa, Shinsuke Iida, et al.
Pageof 29

Showing results (201-210 of 290) with videos related to

Sort By:
Pageof 29
Scientific Reports|May 11, 2019
Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma CellsHiroyuki Yamazaki, Kotaro Shirakawa, Tadahiko Matsumoto, et al.
Cancer Science|July 24, 2019
Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 studyShinsuke Iida, Takashi Watanabe, Morio Matsumoto, et al.
International Journal of Hematology|April 15, 2021
Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patientsMorio Matsumoto, Kenshi Suzuki, Junya Kuroda, et al.
International Journal of Hematology|September 6, 2015
Overexpression of salivary-type amylase reduces the sensitivity to bortezomib in multiple myeloma cellsShohei Mizuno, Ichiro Hanamura, Akinobu Ota, et al.
Cancer Science|October 29, 2017
Clinical significance of tryptophan catabolism in Hodgkin lymphomaAyako Masaki, Takashi Ishida, Yasuhiro Maeda, et al.
International Journal of Hematology|December 31, 2015
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myelomaHaruhito Totani, Masaki Ri, Chie Kato, et al.
Oncotarget|March 9, 2018
Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunitsTakashi Yoshida, Masaki Ri, Takashi Kanamori, et al.
British Journal of Haematology|August 18, 2021
Clinical significance of TP53 mutations in adult T-cell leukemia/lymphomaYuma Sakamoto, Takashi Ishida, Ayako Masaki, et al.
Haematologica|August 5, 2018
Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphomaShiori Kinoshita, Takashi Ishida, Asahi Ito, et al.
Cancer Science|September 6, 2008
Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myelomaHiroki Yano, Satoshi Kayukawa, Shinsuke Iida, et al.
Pageof 29